Genetically Engineered Fusion Proteins for Treatment of Cancer

Cancer Genomics - Proteomics

Britta Schneider¹  Ulrich Brinkmann¹  Ulrich H. Weidle¹  Guy Georges¹ 

[1] Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, GermanyRoche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, GermanyRoche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany

关键词: Angiogenesis;    antibody cytokine fusion proteins;    chimeric extracellular receptor domains;    decoy receptor;    HER signaling;    Fc-based fusion proteins;    immune effector cell recruitment;    treatment resistance;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

In this review, we summarize approaches to treat cancer with genetically engineered fusion proteins. Such proteins can act as decoy receptors for several ligands or as recruiters of immune effector cells to tumor. Examples of interference with growth factor-mediated tumor growth and tumor-related angiogenesis with fusion proteins consisting of the extracellular domains, and in some cases also of entities of one or several receptors and the Fc part of human IgG1, are discussed. In addition, we present strategies for recruitment of immune effector cells to tumor with fusion proteins. This can be achieved with fusion proteins consisting of a tumor-related antibody and a cytokine or major histocompatibilty complex class-I-peptide complexes, by T-cell receptor cytokine fusion proteins or by combination of a T-cell-recruiting antibody with a tumor-related ligand or a defined T-cell receptor.

【 授权许可】

Unknown